1. Erthygl › Ymchwil › Adolygwyd gan gymheiriaid
2. Cyhoeddwyd

   Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden

   Verhoef, T. I., Redekop, W. K., Langenskiold, S., Kamali, F., Wadelius, M., Burnside, G., Maitland-van der Zee, A. H., Hughes, D. & Pirmohamed, M., Hyd 2016, Yn: The Pharmacogenomics Journal. 16, t. 478–484

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

3. Cyhoeddwyd

   Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy

   Plumpton, C., Yip, V. L. M., Alfirevic, A., Marson, A. G., Pirmohamed, M. & Hughes, D., Ebr 2015, Yn: Epilepsia.

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

4. Cyhoeddwyd

   Cost-utility analysis of on demand rabeprazole and esomeprazole for symptomatic gastro oesophageal reflux disease

   Hughes, D., Hughes, D. A. & Dubois, D., 1 Tach 2003, Yn: Value in Health. 6, 6, t. 613

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

5. Cyhoeddwyd

   Costs of Medication Nonadherence in Patients with Diabetes Mellitus: A Systematic Review and Critical Analysis of the Literature.

   Hughes, D., Salas, M., Hughes, D. A., Zuluaga, A., Vardeva, K. & Lebmeier, M., 1 Medi 2009, Yn: Value in Health. 12, 6, t. 915-922

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

6. Cyhoeddwyd

   Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales

   Pijeira Perez, Y., Wood, E. & Hughes, D., 1 Tach 2023, Yn: Orphanet Journal of Rare Diseases. 18, 1, 342.

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

7. Cyhoeddwyd

   Cost–effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs

   Hughes, D., Verhof, T. I., Redekop, W. K., van Schie, R. M., Bayat, S., Daly, A. K., Geitona, M., Haschke-Becher, E., Hughes, D. A., Kamali, F., Levin, L. A., Manolopoulos, V. G., Pirmohamed, M., Siebert, U., Stingl, J. C., Wadelius, M., de Boer, A. & Maitland-van der Zee, A. H., 1 Medi 2012, Yn: Pharmacogenomics. 13, 12, t. 1405-1417

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

8. Cyhoeddwyd

   Current assessment of risk-benefit by regulators: is it time to introduce decision analyses?

   Hughes, D., Hughes, D. A., Bayoumi, A. M. & Pirmohamed, M., 1 Awst 2007, Yn: Clinical Pharmacology and Therapeutics. 82, 2, t. 123-127

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

9. Cyhoeddwyd

   Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

   Hughes, D., Pink, J., Lane, S., Pirmohamed, M. & Hughes D.A., N. V., 31 Hyd 2011, Yn: British Medical Journal. 343, t. 1-14

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

10. Cyhoeddwyd

    Decision analytic modelling methods for the assessing the effectiveness of treatment sequences for clinical and economic decision making: a methodological review

    Lewis, R., Hughes, D. & Wilkinson, C., 30 Tach 2017, Yn: Value in Health. 20, 9, t. A748 1 t.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

11. Cyhoeddwyd

    Decision-Makers’ Preferences for Approving New Medicines in Wales: A Discrete-Choice Experiment with Assessment of External Validity

    Hughes, D., Linley, W. G. & Hughes, D. A., 1 Ebr 2013, Yn: Pharmacoeconomics. 31, 4, t. 345-355

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid